The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Considering the sequencing of CAR T-cell therapy and bispecific antibodies in multiple myeloma
Amrita Krishnan, MD, City of Hope, Duarte, CA, discusses the sequencing of CAR T-cell therapy and bispecific antibodies in multiple myeloma. Dr Krishnan notes that the current paradigm typically involves CAR-T before bispecifics, but as bispecifics evolve, the question of whether CAR-T can be successfully administered after bispecifics remains to be seen. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Sequencing of these therapies is still the million-dollar question. And the reason I say that is because, yes, most of the current paradigm is still CAR-T before bispecific. But as bispecifics evolve and we give them for a fixed duration, then the question becomes if you have a certain interval after a bispecific, perhaps you can do CAR-T quite successfully. So I think the sequencing question still remains to be seen...
Sequencing of these therapies is still the million-dollar question. And the reason I say that is because, yes, most of the current paradigm is still CAR-T before bispecific. But as bispecifics evolve and we give them for a fixed duration, then the question becomes if you have a certain interval after a bispecific, perhaps you can do CAR-T quite successfully. So I think the sequencing question still remains to be seen. The other question is really when you give bispecifics and the mechanism of resistance, if it’s loss of target antigen, that does have implications for CAR T-cell use downstream.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
